DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+33.56%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.42B
AUM Growth
+$5.42B
(+19%)
Cap. Flow
+$277M
Cap. Flow
% of AUM
5.11%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
242
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| 1 |
Oscar Health
OSCR
|
$103M |
| 2 |
Baxter International
BAX
|
$52.5M |
| 3 |
Revolution Medicines
RVMD
|
$38.4M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$36.7M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$34.4M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$41.2M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$38.5M |
| 3 |
Merus
MRUS
|
$23.6M |
| 4 |
Owens & Minor
OMI
|
$23.2M |
| 5 |
Roivant Sciences
ROIV
|
$18.7M |
Sector Composition
| 1 | Healthcare | 78.16% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $1.47B | 27.16% | 19,991,024 | – | – |
|
2
Viatris
VTRS
$12.3B
| $215M | 3.97% | 19,863,484 -1 | -0% | -$11 |
|
3
Catalyst Pharmaceutical
CPRX
$2.52B
| $149M | 2.76% | 8,888,901 +696,901 | +9% | +$11.7M |
|
4
Centene
CNC
$14.3B
| $148M | 2.73% | 1,991,799 +1,799 | +0.1% | +$134K |
|
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $118M | 2.18% | 896,719 -312,995 | -26% | -$41.2M |
|
|
6
Oscar Health
OSCR
$4.31B
| $103M | 1.9% | +11,246,820 | New | +$103M |
|
|
7
Owens & Minor
OMI
$378M
| $101M | 1.86% | 5,229,779 -1,205,221 | -19% | -$23.2M |
|
8
AdaptHealth
AHCO
$1.28B
| $99.2M | 1.83% | 13,607,940 | – | – |
|
|
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
| $94.3M | 1.74% | 2,584,376 +1,004,802 | +64% | +$36.7M |
|
10
IDEAYA Biosciences
IDYA
$2.15B
| $93.6M | 1.73% | 2,630,292 +361,664 | +16% | +$12.9M |
|
|
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $93.4M | 1.72% | 5,788,024 -1,109,582 | -16% | -$17.9M |
|
|
12
Revolution Medicines
RVMD
$7.1B
| $88.6M | 1.64% | 3,090,073 +1,338,577 | +76% | +$38.4M |
|
13
Brookdale Senior Living
BKD
$1.83B
| $86.1M | 1.59% | 14,793,264 +2,113,613 | +17% | +$12.3M |
|
|
14
Merus
MRUS
$4.98B
| $83M | 1.53% | 3,019,901 -857,037 | -22% | -$23.6M |
|
15
Larimar Therapeutics
LRMR
$310M
| $77.1M | 1.42% | 16,941,357 | – | – |
|
16
Kura Oncology
KURA
$686M
| $76.4M | 1.41% | 5,312,733 +938,689 | +21% | +$13.5M |
|
17
Surgery Partners
SGRY
$2.91B
| $67.4M | 1.24% | 2,105,509 +645,509 | +44% | +$20.6M |
|
18
HilleVax
HLVX
$105M
| $64.3M | 1.19% | 4,004,231 | – | – |
|
|
RYZB
19
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $62.6M | 1.16% | 1,006,126 -153,000 | -13% | -$9.51M |
|
|
FUSN
20
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $61.5M | 1.14% | 6,401,000 +3,578,000 | +127% | +$34.4M |
|
21
ARS Pharmaceuticals
SPRY
$1.15B
| $60.7M | 1.12% | 11,077,927 | – | – |
|
|
22
Baxter International
BAX
$12.7B
| $52.5M | 0.97% | +1,358,686 | New | +$52.5M |
|
23
Enhabit
EHAB
$399M
| $51.7M | 0.96% | 4,997,746 | – | – |
|
24
Integra LifeSciences
IART
$1.18B
| $49.2M | 0.91% | 1,128,999 +2,172 | +0.2% | +$94.6K |
|
25
Bio-Rad Laboratories Class A
BIO
$8.06B
| $48.9M | 0.9% | 151,575 -22,372 | -13% | -$7.22M |
|